Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0756
D

Failure to Ensure Proper Notification and Documentation for Antipsychotic Use

Enterprise, Kansas Survey Completed on 11-17-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to ensure that the consultant pharmacist notified the physician or the director of nursing regarding the need for further documentation about the continued use of Risperidone for a resident with an unapproved diagnosis. The resident in question had diagnoses including Lewy body dementia, anxiety disorder, recurrent major depressive disorder, and impulse disorder. The resident's care plan required monthly medication reviews by the consultant pharmacist and physician, as well as documentation of gradual dose reduction attempts and the physician's response. The physician's order specified Risperidone for Lewy Body Dementia with behavioral disturbance, but this is an unapproved diagnosis for the medication, and no rationale for its use was documented by the physician. During the review, it was found that the consultant pharmacist had requested the diagnosis for the use of Risperidone, and the physician responded with the unapproved diagnosis. However, the consultant pharmacist did not follow up to notify the physician or the director of nursing about the need for further documentation to justify the continued use of Risperidone for this unapproved indication. Additionally, the facility was unable to provide a policy on pharmacy reviews when requested. These actions and omissions resulted in a failure to comply with requirements for monthly drug regimen reviews and proper documentation for the use of antipsychotic medications.

An unhandled error has occurred. Reload 🗙